Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexrazoxane - TopoTarget

Drug Profile

Dexrazoxane - TopoTarget

Alternative Names: ADR 529; Dexrazoxane hydrochloride; ICRF 187; KDX-0811; NSC 169780; Savene; Topotect; Totect

Latest Information Update: 10 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TopoTarget
  • Developer Cumberland Pharmaceuticals; Kissei Pharmaceutical; Onxeo SA; TopoTarget
  • Class Adjunct therapies; Chemoprotectants; Piperazines; Small molecules
  • Mechanism of Action Iron chelating agents; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage
  • Discontinued Brain cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Jul 2017 Clinigen and Cumberland Pharmaceuticals obtain FDA approval for dexrazoxane for Chemotherapy induced damage in USA
  • 09 Jan 2017 Dexrazoxane licensed to Cumberland Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top